Tag: Selective reversible MAO-B inhibitor (investigational)

  • Sembragiline

    Selective reversible MAO-B inhibitor (investigational)

    A selective reversible MAO-B inhibitor investigated for Alzheimer disease; failed phase 2 efficacy.

    Abstract

    Sembragiline (EVT-302, RG1577; molecular formula C19H22FN3O; molecular weight 327.40) is a selective reversible MAO-B inhibitor developed at Roche and EVOTEC as a candidate for Alzheimer disease. The mechanistic rationale: MAO-B is upregulated in reactive astrocytes in Alzheimer brain tissue, contributing to oxidative stress and amyloid pathology; selective reversible inhibition might reduce this contribution without the irreversible enzyme abolition of selegiline or rasagiline. Phase 2 MAyflOwer RoAD trial in mild-to-moderate Alzheimer disease (n=542) failed to show significant slowing of cognitive decline at 52 weeks; development was halted. The compound retains research utility as a clean tool for selective reversible MAO-B inhibition (selectivity ratio greater than 1000:1 over MAO-A) and is used in academic studies of MAO-B’s role in neurodegeneration. Used as the reference reversible selective MAO-B inhibitor in academic neuroscience.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.